IP Library Granted Patent US 11,413,264
Granted Patent B2
US 11,413,264 · App. 16/634,935 · Granted Aug 16, 2022

Carbamoyl phenylalaninol analogs and uses thereof

Inventor: Fionn Hurley (Baldoyle, IE)
Assignee: Jazz Pharmaceuticals Ireland Limited
A61K31/27A61K31/165A61K31/17A61K31/255C07C233/11C07C275/24C07C307/02C07C333/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,264
App. No.
16/634,935
Granted
Aug 16, 2022
Kind
B2
Abstract

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

Claims (21)

1. A compound of Formula V:

or a pharmaceutically acceptable salt thereof, wherein:

Z is S;

Y is C═S or SO 2 ;

R is optionally substituted C 1-8 alkyl, halogen, optionally substituted C 1-4 alkoxy, cyano, hydroxy, optionally substituted trifluoromethyl, or C 1-4 thioalkoxy;

n is 0, 1, 2, or 3, with the proviso that R may be the same or different when n is 2 or 3; and

R 1 and R 2 can be the same or different and are independently selected from the group consisting of hydrogen, optionally substituted C 1-8 alkyl, optionally substituted amide, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, and optionally substituted C 3-7 cycloalkyl;

or R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle optionally substituted with alkyl or aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The compound of claim 1 , having Formula Va:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , having Formula VIa:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is the hydrochloride salt.

5. A composition comprising the compound of claim 1 .

6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

7. The composition of claim 6 , wherein the composition is a dosage form.

8. The composition of claim 7 , wherein the composition is an immediate release oral dosage form.

9. The composition of claim 8 , wherein the composition is a tablet or a capsule.

10. A kit comprising the compound of claim 1 .

11. The compound of claim 1 , wherein R 1 and R 2 are hydrogen.

12. The compound of claim 1 , wherein n is 0.

Assignments (6)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
RELEASE OF SECURITY INTEREST Recorded May 6, 2025
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR IN INTEREST TO U.S. BANK NATIONAL ASSOCIATION
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 071034/0467 →
SECURITY INTEREST Recorded Sep 9, 2024
From: AXSOME MALTA LTD
To: HERCULES CAPITAL, INC.
Reel/Frame 068900/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: JAZZ PHARMACEUTICALS IRELAND LIMITED
To: AXSOME MALTA LTD.
Reel/Frame 060223/0878 →
SECURITY AGREEMENT Recorded May 5, 2021
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056151/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2020
From: HURLEY, FIONN
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 053393/0077 →